The role of probiotic lactic acid bacteria and bifidobacteria in the prevention and treatment of inflammatory bowel disease and other related diseases: a systematic review of randomized human clinical trials.
The role of probiotic lactic acid bacteria and bifidobacteria in the prevention and treatment of inflammatory bowel disease and other related diseases: a systematic review of randomized human clinical trials.
复制标题
DOI：
10.1155/2015/505878
复制
发表时间：
2015
影响因子：
--
通讯作者：
Gil A
中科院分区：
文献类型：
--
作者：
Saez-Lara MJ;Gomez-Llorente C;Plaza-Diaz J;Gil A
炎症性肠病(IBD)包括克罗恩病(CD)和溃疡性结肠炎(UC)，是一种由于遗传易感人群对宿主肠道微生物区系的免疫反应失调而导致的小肠和结肠的慢性炎症。一些发酵乳制品含有乳酸菌(LAB)和双歧杆菌，其中一些已被鉴定为益生菌，可以改变肠道微生物区系，可能有利于IBD的治疗和预防。这篇综述的目的是利用PubMed和Scope数据库对实验室和双歧杆菌益生菌和IBD进行系统的搜索，这些数据库由使用网格项的特定方程定义，并限于人类临床试验。益生菌和/或合生菌的使用在治疗和维持UC方面有积极的效果，而在CD中，只有合生菌才显示出明显的有效性。此外，在其他相关的IBD病理中，如膀胱炎和胆管炎，乳酸菌和双歧杆菌益生菌可以通过改善临床症状而受益。然而，还需要更多的研究来了解它们的作用机制，并在将益生菌用作治疗和预防IBD疾病的辅助剂之前了解它们的效果。
Inflammatory bowel disease (IBD), which includes Crohn's disease (CD) and ulcerative colitis (UC), is a chronic inflammation of the small intestine and colon caused by a dysregulated immune response to host intestinal microbiota in genetically susceptible subjects. A number of fermented dairy products contain lactic acid bacteria (LAB) and bifidobacteria, some of which have been characterized as probiotics that can modify the gut microbiota and may be beneficial for the treatment and the prevention of IBD. The objective of this review was to carry out a systematic search of LAB and bifidobacteria probiotics and IBD, using the PubMed and Scopus databases, defined by a specific equation using MeSH terms and limited to human clinical trials. The use of probiotics and/or synbiotics has positive effects in the treatment and maintenance of UC, whereas in CD clear effectiveness has only been shown for synbiotics. Furthermore, in other associated IBD pathologies, such as pouchitis and cholangitis, LAB and bifidobacteria probiotics can provide a benefit through the improvement of clinical symptoms. However, more studies are needed to understand their mechanisms of action and in this way to understand the effect of probiotics prior to their use as coadjuvants in the therapy and prevention of IBD conditions.
登录
查看更多内容
影响因子：
3.1
作者：
D'Inca, Renata;Barollo, Michela;Sturniolo, Giacomo Carlo
通讯作者：
Sturniolo, Giacomo Carlo
影响因子：
5.2
作者：
Click, Robert E.
通讯作者：
Click, Robert E.
影响因子：
3.9
作者：
Gionchetti, Paolo;Rizzello, Fernando;Campieri, Massimo
通讯作者：
Campieri, Massimo
影响因子：
3.7
作者：
Friedman, S
通讯作者：
Friedman, S
影响因子：
3.1
作者：
Chermesh, Irit;Tamir, Ada;Eliakim, Rami
通讯作者：
Eliakim, Rami